Oruka Therapeutics’ (ORKA) “Buy” Rating Reaffirmed at BTIG Research

BTIG Research reissued their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research note published on Monday,Benzinga reports. The firm currently has a $56.00 price target on the stock.

Several other analysts have also issued reports on the company. Wall Street Zen raised Oruka Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. Wedbush reissued an “outperform” rating and set a $40.00 price target on shares of Oruka Therapeutics in a report on Tuesday, August 12th. Finally, HC Wainwright reissued a “buy” rating and set a $45.00 price target on shares of Oruka Therapeutics in a report on Monday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating and four have assigned a Buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $42.00.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock opened at $18.62 on Monday. The stock has a market cap of $697.32 million, a PE ratio of -6.63 and a beta of -0.29. Oruka Therapeutics has a one year low of $5.49 and a one year high of $31.13. The stock has a fifty day moving average of $15.20 and a 200 day moving average of $12.53.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.02. As a group, sell-side analysts predict that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Hedge Funds Weigh In On Oruka Therapeutics

Hedge funds have recently made changes to their positions in the business. Legal & General Group Plc bought a new position in shares of Oruka Therapeutics in the second quarter worth about $28,000. Ameritas Investment Partners Inc. bought a new position in shares of Oruka Therapeutics in the second quarter worth about $31,000. BNP Paribas Financial Markets boosted its stake in shares of Oruka Therapeutics by 464.0% in the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after acquiring an additional 2,306 shares during the period. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Oruka Therapeutics in the second quarter worth about $68,000. Finally, New York State Common Retirement Fund bought a new position in shares of Oruka Therapeutics in the second quarter worth about $96,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.